EN DE

YSB Inc (9885) Fair Value & Analysis

Healthcare · HK · Market cap HK$3.1B

YI YSB Inc 9885 · HK
PriceHK$3.37
Fair ValueHK$4.12
Upside+22.4%
Quality46/100
Watch YSB Inc for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 0.7% net margin
generates free cash flow
2.55% dividend yield
Ranks above peers (8/13)
Narrow moat 20/100
Evidence: High Range HK$3.27 – HK$5.30 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 3 days ago

Fair value updated Aug 13, 2026, revised from HK$4.38 to HK$4.12 (−5.9%) since Aug 6, 2026. Share price −3.9% over the past month.

Below-average quality, screening 22% undervalued on our models.

What matters now

  • Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality.
  • Our model range runs from HK$3.27 (bear) to HK$5.30 (bull), base HK$4.12. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 46/100 (below-average quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (3 years)

HK$59.25 HK$3.05 Fair Value HK$4.12 Jun 2023 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

38‑month range HK$3.05 – HK$59.25 · fair‑value band HK$3.27 – HK$5.30 · the HK$3.37 price screens below the HK$4.12 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

YSB Inc (9885) currently trades at HK$3.37, while our model-based Fair Value estimate is HK$4.12, implying the stock looks roughly 22.4% undervalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, YSB Inc generated revenue of HK$21.0B at a net margin of 0.7%. Revenue grew 22.4% year over year. It earns a return on equity of 6.3%. Net debt stands at HK$423M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$3.27 (bear case) to HK$5.30 (bull case); at HK$3.37, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 72% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 22%, 9885 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income HK$2.77 HK$2.86 HK$2.89 76
Growth DCF HK$15.93 HK$27.51 HK$48.44 72
Gordon GGM HK$0.6500 HK$1.29 HK$1.95 70
All 26 models by family
DCF Models
FCF DCF HK$16.51 HK$25.38 HK$49.41 38
Owner Earnings HK$9.48 HK$16.63 HK$30.87 31
5Y Revenue Exit HK$7.90 HK$9.54 HK$12.10 39
5Y EBITDA Exit HK$9.37 HK$12.76 HK$18.25 41
5Y P/E Exit HK$9.67 HK$13.98 HK$19.16 38
10Y Revenue Exit HK$10.51 HK$13.71 HK$16.73 36
10Y EBITDA Exit HK$11.55 HK$16.37 HK$24.02 37
10Y P/E Exit HK$11.75 HK$16.92 HK$24.86 35
Earnings-Based
Graham-Dodd HK$1.51 HK$10.22 HK$14.32 54
Lynch FV HK$3.00 HK$4.28 HK$5.57 50
PEG = 1.0 HK$3.00 HK$4.28 HK$5.57 46
EPV HK$4.11 HK$4.22 HK$4.32 59
Dividend Discount
Gordon GGM HK$0.6500 HK$1.29 HK$1.95 70
DDM Multi-Stage HK$0.6500 HK$1.11 HK$1.36 61
Multiples
P/E Multiple HK$3.49 HK$4.66 HK$5.82 63
P/S Multiple HK$2.83 HK$3.77 HK$4.71 58
P/B Multiple HK$2.83 HK$3.77 HK$4.71 55
EV/EBIT HK$4.56 HK$4.95 HK$5.34 53
EV/EBITDA HK$6.45 HK$7.46 HK$8.48 54
EV/Revenue HK$4.23 HK$4.59 HK$4.94 43
Asset-Based
NCAV (Graham) HK$1.77 HK$2.37 HK$3.54 50
Growth DCF
Growth DCF HK$15.93 HK$27.51 HK$48.44 72
Rev-Margin DCF HK$7.90 HK$9.94 HK$12.87 67
Economic Profit
Residual Income HK$2.77 HK$2.86 HK$2.89 76
ROIC Compounder HK$4.22 HK$4.47 HK$4.79 67
Growth Earnings
Growth-Adj P/E HK$4.15 HK$5.92 HK$7.70 68

Widest divergence: DCF Models (HK$13.98) versus Dividend Discount (HK$1.11). Highest evidence: Residual Income (76).

Notify me when 9885 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$21.0B
Revenue growth (YoY) +22.4%
Net margin 0.7%
Return on equity 6.3%
Free cash flow HK$619M FY2025
P/E ratio 18.2 as of Jul 3, 2026
More key figures
Operating margin 0.2%
EPS (TTM) HK$0.1100
Dividend yield 2.6%
EPS growth (YoY) +769%
Net debt HK$423M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 46/100

Of which business quality 51 · Market factors (momentum, volatility) 20

Profitability 46
Margins and returns on capital today
Quality Growth 63
Are margins and returns improving?
Cashflow 62
Earnings quality: real cash, not paper profit
Fin. Strength 64
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 49
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 12
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

YSB Inc. operates a digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China.

Full company description

YSB Inc. operates a digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. The company offers ClouMinihouse, a primary smart healthcare system that includes Future Lou, a series of advanced point-of-care testing and monitoring devices; Cloud consultation SaaS, a digital clinic management system; and ClouWiseDoctor, a smart AI doctors-aid system. It also provides SaaS solutions; and YSB eLearn that provides online courses for the preparation of the pharmacist qualification examinations. In addition, the company engages in the wholesale and retail of pharmaceutical and healthcare products. Further, it provides medical testing services; logistics services; and ClouDiagnos. YSB Inc. was founded in 2015 and is headquartered in Guangzhou, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

YSB Inc reported revenue of HK$21.0B in FY2025 versus HK$10.1B in FY2021, a compound +20.1%/yr. Reported net income was HK$153M in FY2025.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$21.0B
Latest YoY
+17.1%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.7%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+28.2%
Revenue +20.1%/yr
FY21 HK$10.1B
FY22 HK$14.3B
FY23 HK$17.0B
FY24 HK$17.9B
FY25 HK$21.0B
Net income
FY21 −HK$502M
FY22 −HK$1.5B
FY23 −HK$3.2B
FY24 HK$30.0M
FY25 HK$153M

Watch 9885: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

YSB Inc · Fair Value
HK$4.12 +22%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "YSB Inc Fair Value". https://www.fairvalue-calculator.com/stock/9885

Peer Group

Pharmaceutical Retailers · 63 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 46 · Below median
Fair Value upside +22% · Top 25%
Return on equity (TTM) 6% · Above median
Return on assets 1% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 0% · Below median
Revenue growth 22% · Top 25%
Dividend yield (TTM) 2.6% · Below median

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 18.2× · Cheaper than median
P/B 1.28× · Cheaper than median
P/S (TTM) 0.15× · Cheaper than 75% of peers
P/FCF 0.6× · Cheaper than median
EV/EBITDA 5.9× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 63 · sector 25
FUTURE 100 · sector 17
PAST 25 · sector 15
HEALTH 0 · sector 97
DIVIDEND 51 · sector 63

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc 6618 HK$38.86 HK$33.31 -14%
Alibaba Health Information Technology Limited 0241 HK$3.33 HK$2.04 -39%
Raia Drogasil S.A RADL3 R$18.00 R$15.58 -13%
Yifeng Pharmacy Chain Co 603939 ¥24.03 ¥29.07 +21%
DaShenLin Pharmaceutical Group 603233 ¥18.14 ¥23.86 +32%
Corporativo Fragua, S.A. FRAGUAB 463.00 MXN 726.02 MXN +57%
LBX Pharmacy Chain Joint Stock Company 603883 ¥13.44 ¥10.57 -21%
MedPlus Health Services Limited MEDPLUS ₹675.05 ₹379.25 -44%
Yixintang Pharmaceutical Group 002727 ¥12.29 ¥9.45 -23%
Anhui Huaren Health Pharmaceutical Co 301408 ¥16.51 ¥10.05 -39%

Compare YSB Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is YSB Inc (9885) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$4.12 versus a price of HK$3.37, about +22% (undervalued).
What is the fair value of 9885?
Our model-based fair value for YSB Inc is HK$4.12 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$3.37.
What is the quality score of 9885?
YSB Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of YSB Inc (9885)?
YSB Inc reported trailing-twelve-month revenue of about HK$21.0B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 9885?
The net profit margin of YSB Inc is about 0.7%, meaning it keeps roughly 0.7% of revenue as net income. Based on the latest reported figures.
Does YSB Inc pay a dividend?
YSB Inc currently shows a dividend yield of about 2.55% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track YSB Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.